We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




FDA Approves First of its Kind Companion Dx for Lung Cancer Patients

By LabMedica International staff writers
Posted on 02 Nov 2015
The US Food and Drug Administration (FDA) have approved the first complementary diagnostic test to support use of OPDIVO (nivolumab) for non-squamous non-small-cell lung cancer (NSCLC) therapy.

Historically, the one-year overall survival in the second-line treatment of NSCLC has been about 26%. More...
The new test, “PD-L1 IHC 28-8 pharmDx” from Dako Denmark A/S (Glostrup, Denmark), an Agilent Technologies company, is a qualitative immunohistochemical (IHC) assay that can identify PD-L1 expression levels on the surface of NSCLC tumor cells and provide information on the survival benefit of therapy with OPDIVO for patients with non-squamous NSCLC. Dako developed the diagnostic through collaboration with Bristol-Myers Squibb, maker of OPDIVO, an immuno-oncology therapy FDA-approved for treatment of patients with previously treated NSCLC.

Dako’s test was used to assess PD-L1 expression in the Phase-3 CheckMate 057 trial, in which OPDIVO demonstrated superior overall survival in patients with previously treated metastatic non-squamous NSCLC compared to chemotherapy. The FDA on October 9, 2015, expanded the indication for OPDIVO to include previously treated non-squamous NSCLC in addition to the squamous NSCLC indication. PD-L1 IHC 28-8 pharmDx is the first and only diagnostic assay FDA-approved to assess survival benefit associated with OPDIVO. PD-L1 testing is not required for use of OPDIVO, but it may provide additional information for physicians and inform patient dialogue.

"We are excited about Agilent's involvement in these advancements and the potential PD-L1 IHC 28-8 pharmDx has in helping to provide information to oncologists considering OPDIVO for patients with non-squamous NSCLC," said Jacob Thaysen, president, Diagnostics and Genomics Group, Agilent.

"We are proud to announce the recent FDA approval of OPDIVO based upon overall survival in an expanded indication for all appropriate patients with previously treated metastatic NSCLC," added Michael Giordano, senior vice president and head of Development, Oncology, Bristol-Myers Squibb, "Our collaboration with Dako underscores our leadership in cancer innovation and our commitment to advancing research evaluating the potential role of PD-L1 in multiple tumor types."

Related Links:

Dako 
PD-L1 IHC 28-8 pharmDx
Agilent Technologies



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.